CORD-19:2e2bc679c8393230bac2af64115bab7ed1ba62c0 / 509458-509565 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T95","span":{"begin":0,"end":107},"obj":"Sentence"}],"text":"Conclusions RCA with Prismocitrate 10/2 reduces the incidence of metabolic alkalosis associated with ACD-A."}

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T38591","span":{"begin":0,"end":107},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Conclusions RCA with Prismocitrate 10/2 reduces the incidence of metabolic alkalosis associated with ACD-A."}

    CORD-19-PD-HP

    {"project":"CORD-19-PD-HP","denotations":[{"id":"T1012","span":{"begin":65,"end":84},"obj":"Phenotype"}],"attributes":[{"id":"A1012","pred":"hp_id","subj":"T1012","obj":"http://purl.obolibrary.org/obo/HP_0200114"}],"text":"Conclusions RCA with Prismocitrate 10/2 reduces the incidence of metabolic alkalosis associated with ACD-A."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1561","span":{"begin":101,"end":104},"obj":"Disease"},{"id":"T1510","span":{"begin":101,"end":104},"obj":"Disease"}],"attributes":[{"id":"A1561","pred":"mondo_id","subj":"T1561","obj":"http://purl.obolibrary.org/obo/MONDO_0011855"},{"id":"A1562","pred":"mondo_id","subj":"T1561","obj":"http://purl.obolibrary.org/obo/MONDO_0021808"},{"id":"A43711","pred":"mondo_id","subj":"T1510","obj":"http://purl.obolibrary.org/obo/MONDO_0011855"},{"id":"A75686","pred":"mondo_id","subj":"T1510","obj":"http://purl.obolibrary.org/obo/MONDO_0021808"}],"text":"Conclusions RCA with Prismocitrate 10/2 reduces the incidence of metabolic alkalosis associated with ACD-A."}